ClinicalTrials.Veeva

Menu
B

BLC Clinical Research | Burlington, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BI 1291583
Nalbuphine
DUPIXENT®
NOC-110
Verducatib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 5 total trials

A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

This study is for adults and adolescents who are at least 12 years old and have bronchiectasis. People can participate if they completed a previous s...

Begins enrollment in 1 month
Bronchiectasis
Drug: verducatib

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalatio...

Active, not recruiting
Refractory or Unexplained Chronic Cough
Drug: NOC-110
Other: Placebo

This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and...

Enrolling
Bronchiectasis
Drug: Placebo matching BI 1291583
Drug: BI 1291583

The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.

Enrolling
Refractory Chronic Cough
Drug: NAL ER
Drug: Placebo

Trial sponsors

Boehringer Ingelheim logo
N
Regeneron Pharmaceuticals logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems